4Charles EC,Olson KL,Sandhoff BG,et al.Evaluation of cases of severe ststin-related transaminitis within a large health maintenance organization.Am J Med,2005,118:618-624.
5Vasilios GA,Konstsntinos T,Thomas DG.Safety and efficacy of long-term statin reatment for cardiovasctlar events in patients with coronary heart disease and abnormal liver tests in GREACE Study:a post-hoc analysis.Lancet,2010,376:1916-1922.
6Daniel GH,Fangyun Wu.Statins and renovascular disease in the elderly.Eur Heart J,2011,32(5):598-610.
7Douglas K,O' Malley PG,Jackson JL.Meta-analysis:the effeot of statins on albuminuria.Ann Intern Med,2006,145:117-124.
8TonelliM,Isles C,Curhan GC,et al.Effect of pravastatin on cardiovascular events in people with chronic kidney disease.Circulation,2004,110:1557-1563.
9Kimura K,Shimano H,Yokote K,et al.Effects of pitavastatin (LIVALO tablet) on the estinated glomerular filtration rate (eGFR) in hypercholeste1rolemic patients with chronic kidney disease.J Atheroscler Thromb,2010,17(6):601-609.
10Bae EH,Kim U,Park JW,et al.Renopr oteetive effect of rosuvastatin in DOCA--salt hypertensive rats.Nephrol Dial Transplant,2010,25:1051-1059.
二级参考文献17
1[1]Scandinavian Simvastatin Sur vival Study Group.Randomized trial of ch olesterol lowering in 4444 patients with coronary heart disease:the Scandinavan Simvastatin Survival Study(4S). Lancet,1994,344:1383-1389.
2[2]The long-term Intervention with P ravastatin in Ischemic Disease(LIPID )Stud y Group.Prevention of cardiovascular eve nts and death with pravastatin in patien ts with coronary heart disease and a bro ad rang of initial cholesterol levels.N Engl J Med,1998,339:1349-1357.
3[3]Forrester JS.Role of plaque ruptu re in acute coronary syndromes.Am J Card iol,2000,86(suppl.):155-235.
4[4]Selwyn AP,Kinlay S,Libby P,et al .Atherogenic lipids,vascular dysfunction ,and clinical signs of ischemic heart di sease.Circulation,1997,95:5-7.
5[5]Dupuis J,Tardif JC,Cernacek P,et al.Cholesterol reduction rapidly improve s endothelium function after acute coron ary syndrome:the RECIFE(Reduction of Cho lesterol in Ischemia and Function of the Endothelium)trial[see comm ents].[ BFQ〗Circulation,1999,99:3227-3233.
6[6]ODriscoll G,Green D,Taylor RR.Simvast atin an HMG-coenzyme a reductase inhibit or,improves endothelial function within 1 month.Circulation,1997,95:1126-1131.
7[7]Treasure CB,Klein JL,Weintraub WS ,et al.Beneficial effects of cholesterol -lowering therapy on the coronary endoth elium in patients with coronary artery d isease.N Engl Med,1995,332:481-487.
8[8]Niwa S,Totsuka Y,Hayshi S.Inhibit ory effect of fluvastatin,an HMG-CoA red uctase inhibitor,on the expression of ad hesion molecules on human monocytes cell line.Int J Immunopharmacol,1996,18:669- 675.
9[9]Bustos C,Hernandez-Presa MA,Ortego M,e t al.HMG-CoA reductase inhibition by ato rvastatin reduces neointimal inflammatio n in a rabbit model of atherosclerosis.J Am Coll Cardiol,1998,32:2057-2064.
10[10]Albert MA,Danielson E,Rifai N,et al.Effect of statin therapy on creactiv e protein levels:the pravastatin inflamm ation/CRP evaluation(PRINCE):a randomizen trial and cohort study.JAMA,2 001,286:64-70.
